The law firm of Kirby McInerney LLP is investigating potential claims against Vanda Pharmaceuticals, Inc. (Vanda or the Company) (NASDAQ: VNDA). This investigation concerns whether Vanda has violated federal securities laws and/or engaged in other unlawful business practices.
On February 11, 2019, Aurelius Value published an article reporting that a qui tam lawsuit filed by a whistleblower was recently unsealed, containing allegations of illegal off-label promotion of both of Vandas drugs, Vandas participation in a fraud involving doctors writing hundreds of ˜fake prescriptions and pocketing cash using Vanda-issued copay cards, falsified documents in internal systems, and resignations of senior executives who refused to participate in illegal activity.
On this news, shares of Vanda fell $0.95 per share or approximately 5%, to close at $18.00 on February 11, 2019.
If you acquired Vanda securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at [email protected], or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.
Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, and whistleblower litigation. The firms efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLPs website: www.kmllp.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.